The parapoxvirus orf virus causes pustular dermatitis in sheep and is transmissible to humans. The virus encodes a secreted chemokine-binding protein (CBP). We examined the ability of this protein to inhibit migration of murine monocytes in response to CC inflammatory chemokines, using chemotaxis assays, and its effects on monocyte recruitment into the skin, using a mouse model in which inflammation was induced with bacterial lipopolysaccharide. CBP was shown to bind murine chemokines CCL2, CCL3 and CCL5 with high affinity by surface plasmon resonance and it completely inhibited chemokine-induced migration of monocytes at a CBP : chemokine molar ratio of 4 : 1. In the mouse, low levels of CBP potently inhibited the recruitment of Gr-1 + / CD11b + monocytes to the site of inflammation in the skin but had little effect on neutrophil recruitment, suggesting that this factor plays a role in disrupting chemokine-induced recruitment of specific immune cell types to infection sites.
The parapoxvirus orf virus (ORFV) induces acute, highly vascularised cutaneous pustular lesions in sheep and goats and is transmissible to humans (Haig & Mercer, 1998) . The benign lesions resolve in approximately 4-6 weeks. Virus replication is specific to keratinocytes (Haig & Mercer, 1998) and there is no evidence of systemic infection. Despite an apparent potent inflammatory response and normal cell-mediated response, ORFV is able to reinfect its host (Haig et al., 2002) . The discovery of several secreted immunomodulators encoded by the virus may explain this phenomenon. These include a homologue of interleukin (IL)-10 (Fleming et al., 1997) , a vascular endothelial growth factor (Lyttle et al., 1994) , a dual-specificity granulocyte-macrophage colony-stimulating factor IL-2binding protein (Deane et al., 2000) and a chemokinebinding protein (CBP) (Seet et al., 2003) . These factors are thought to work in concert to suppress inflammation and innate immunity and delay the development of adaptive immunity (reviewed by Fleming & Mercer, 2007) .
Chemokines are a large family of secreted chemotactic proteins that regulate inflammation-induced leukocyte recruitment to sites of infection, as well as homeostatic migration of leukocytes through lymphoid organs (Baggiolini, 1998; Cyster, 1999) . Chemokines bind and transduce signals through distinct members of the G protein-coupled receptor superfamily (Rossi & Zlotnik, 2000) . Members of the chemokine family are classified as CC, CXC, CX 3 C and C based on the arrangement of cysteine residues at the N terminus (Rollins, 1997) . In general, CC chemokines are chemoattractants for monocytes (Uguccioni et al., 1995) whereas CXC chemokines are potent chemoattractants of neutrophils or lymphocytes (Larsen et al., 1989) . Lymphotactin (C chemokine) is a chemoattractant for lymphocytes, NK cells, neutrophils and B cells (Huang et al., 2001) . In innate immunity, chemokines establish concentration gradients by attaching to the extracellular matrix through glycosaminoglycan binding domains, by which leukocytes are recruited to sites of inflammation (Yu et al., 2005) .
ORFV strain NZ2 CBP has no mammalian homologue, shares low sequence identity (,17 %) to other poxvirus and herpesvirus CBPs and has a unique chemokine binding profile (Seet et al., 2003) . Surface plasmon resonance revealed that ORFV NZ2 -CBP binds a wide range of human CC chemokines and the C chemokine lymphotactin with high affinity, but does not bind CXC chemokines. We predict that the ORFV CBP secreted into the skin epithelium by the virus competes with chemokines for their cognate receptors and thereby sets up a blockade around the site of the lesion to inhibit the recruitment of leukocytes. Here, we report the ability of the ORFV NZ2 -CBP to inhibit the migration of murine monocytes in response to specific inflammatory chemokines, using chemotaxis assays, and its ability to impair the recruitment of these cells in a murine skin inflammation model. Monocytes are derived from bone marrow progenitors and are central players in both innate and adaptive immunity because of their endocytic activity and their ability to differentiate into antigen-presenting cells (Imhof & Aurrand-Lions, 2004) .
The predominant chemokines produced during damage and inflammation of epithelial tissues are CCL2 (MCP-1), CCL3 (MIP-1a) and CCL5 (RANTES) (Kopydlowski et al., 1999; Wetzler et al., 2000) . We investigated the binding affinity kinetics of ORFV NZ2 -CBP for these murine chemokines using surface plasmon resonance (Biacore). ORFV NZ2 -CBP-FLAG was expressed and purified as previously described (Seet et al., 2003) . The surface of a CM-5 chip was coated with approximately 300-400 response units (pg mm 22 ) of CBP-FLAG by standard amine coupling. All experiments were performed at 25 u C with HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005 % polysorbate 20, pH 7.4). The coupled CBP was exposed to murine chemokines at a flow rate of 100 ml min 21 , at concentrations ranging from 3 to 300 nM for the duration of 60 s. Chemokines were injected over the blank control and the coupled CBP-FLAG flow cells. Following an association period of 30 s, HBS-EP was injected over both surfaces to monitor the dissociation phase of binding. Chemokines were allowed to dissociate for 200 s before the surface was regenerated using a mixture of ionic and acidic solutions. The data were analysed using BIAevaluation software using the 1 : 1 protocol for binding with mass transfer. The binding affinities of CBP-FLAG to murine chemokines were as follows: CCL2, 0.406 nM; CCL3, 0.14 nM; CCL5, 0.03 nM. The high affinity interactions are the result of very fast association kinetics (K on .10 7 M 21 s 21 ) and slow dissociation kinetics (K off ,10 23 s 21 ) (see Supplementary Table S1 , available in JGV Online). The binding affinity of CBP-FLAG for the murine inflammatory chemokines tested was similar to that found for human chemokines (Seet et al., 2003) .
Next, we investigated the ability of CBP-FLAG to block the migration of monocytes in chemotaxis assays in response to murine CCL2, CCL3 and CCL5. Monocytes were generated from C57BL/6 mouse bone marrow and cultured in the presence of 10 % M-CSF for 5 days (Schuetze et al., 2005) . By this time, monocytes were 90 % positive for CD11b (allophycocyanin-conjugated rat anti-mouse integrin/CD11b, clone M1/70, isotype rat IgG 2b ; R&D Systems) and expressed low levels of MHC-II (phycoerythrinconjugated rat anti-mouse I-A/I-E, clone M5/114.15.2, isotype rat IgG 2b , k; BD Biosciences) ( Supplementary Fig.  S1 , available in JGV Online).
Chemotaxis assays were performed with transwells containing 5 mm membrane inserts (Costar) with recombinant murine chemokines CCL2, CCL3 and CCL5 (R&D Systems). Monocytes were added to the top chamber of the transwell assay system at 1610 5 cells ml 21 and chemokines were added to the bottom chamber. To ensure maximal cell migration, the assay was optimized for chemokine concentration and incubation time. We noted that some cells adhered to the bottom of the membrane while other cells migrated entirely through the membrane into the medium in the lower chamber. Others have reported similar findings using this assay system (Dieu-Nosjean et al., 1999) . Cells on the underside of membranes were counted over four fields and averaged as described previously (Sozzani et al., 1997) . Cells that migrated through the membrane into the medium were counted using flow cytometry (FACSCalibur, BD BioSciences; Cellquest software). We observed a dose-response relationship for all chemokines tested. The concentrations of CCL2, CCL3 and CCL5 that induced a four-to sixfold increase in monocyte migration were 50, 12.5 and 25 ng ml 21 , respectively ( Supplementary Fig. S2 , available in JGV Online). The optimal migration time of 3 h was consistent with published data (Wang et al., 1993) .
We then tested the ability of CBP-FLAG to block migration in response to the inflammatory chemokines. Titrations of CBP-FLAG were added simultaneously with the optimal amount of chemokine (determined above) added to the bottom chamber. After 3 h incubation, migrant cells adhered to membranes or in medium in the bottom chamber were quantified as described above. CBP-FLAG reduced chemokine-induced migration of monocytes in a dose-dependent manner (Fig. 1) . For all three chemokines, inhibition of monocyte migration by CBP-FLAG was significant for a chemokine : CBP-FLAG molar ratio of 1 : 1 (P,0.05), with the exception of CCL2 (adherent cells only). The highest inhibition was observed with a CBP-FLAG : chemokine molar ratio of 4 : 1 that reduced migration to background levels (cells only control).
We then investigated whether these in vitro findings translated into inhibition of monocyte recruitment during acute inflammation in vivo. The animal experiments described were approved by the Animal Ethics Committee, University of Otago. The injection of small amounts of lipopolysaccharide (LPS) results in highly localized inflammation and predominantly the upregulation of the inflammatory chemokines CCL2, CCL3 and CCL5 (Charo & Ransohoff, 2006; Haberstroh et al., 2002) .
In preliminary experiments, we determined the optimal levels of LPS (in 20 ml) to inject into the dermis of the shaved abdomen of C57BL/6 mice and the time at which maximal monocyte recruitment was evident. Evans blue dye (2 ml of 1 % solution) was added to each sample to visualize the diffusion of injected material and to identify the site of injection of LPS 24 h post-treatment, when animals were sacrificed and approximately equal areas of skin were excised. Cells were isolated from the skin by treatment with collagenase and dispase, phenotyped for the cell surface markers Gr-1 (anti-Gr-1 allophycocyaninconjugated, clone RB6-8C5, isotype IgG 2b ; R&D Systems) and CD11b (biotinylated anti-mouse CD11b, clone M1/ 70, isotype IgG 2b ; BD Biosciences), which together identify inflammatory monocytes (Geissmann et al., 2003) , and were analysed by flow cytometry. The results showed a sixfold increase in monocyte recruitment using 1 mg LPS and the response was maximal at 24 h posttreatment ( Supplementary Fig. S3 , available in JGV Online).
Animals were co-injected with 1 mg LPS with or without various amounts of CBP-FLAG (total volume 20 ml). After 24 h, skin was excised from the injection sites and weighed; cells were isolated and stained as described above. Total cells were determined by haemocytometer enumeration. From the flow cytometric analysis of 10 000 cells and the total cell count, the number of monocytes (mg skin) 21 was determined. Fig. 2(a) shows that 100 and 1 ng of CBP-FLAG significantly inhibited recruitment for Gr-1 + / CD11b + monocytes (P,0.01, paired Student's t test), whereas with 0.01 ng of CBP-FLAG, the cell numbers were similar to the PBS control. From phenotype marker analysis, a population of Gr-1 + /CD11b 2 cells was identified. These cells represent granulocytes or neutrophils (Ishikawa & Miyazaki, 2005) . CBP-FLAG did not have an effect on the recruitment of these cell types, which remained constant regardless of the dose of CBP-FLAG (Fig. 2b) .
In addition, we wished to establish whether CBP-FLAG could impair recruitment of blood-derived monocytes to the skin. To investigate this using the mouse model, we isolated bone marrow cells from enhanced green fluorescent protein (eGFP) transgenic C57BL/6 donor mice and Fig. 1 . CBP-FLAG inhibits monocyte migration in response to inflammatory chemokines. Chemotaxis assays were performed using a transwell assay system. CCL2 (a), CCL3 (b) and CCL5 (c) were used at 50, 12.5 and 25 ng ml "1 , respectively. CBP-FLAG was added to give the molar ratios shown (CCL : CBP). The fold increase represents the migration of monocytes compared with the cells only control. Membrane-adherent cells (dark grey bars) and cells that have migrated through to the bottom chamber (light grey bars) are shown. The data are shown as mean±SD of four combined experiments, in which each assay was performed in duplicate. Results significantly different to CCL only (P,0.05; ANOVA, Tukey's test) are indicated by asterisks. Fig. 2 . CBP-FLAG inhibits LPS-induced recruitment of Gr-1 + / CD11b + inflammatory monocytes into the skin. Mice were injected in the dermis with LPS (1 mg) with and without CBP. In addition, each mouse received injections of CBP only and PBS i.e. a total of four injections per mouse (n53 animals per group). At 24 h postinjection, cells were isolated from skin and stained for Gr-1 and CD11b. Untreated skin was also included. Cell counts are shown for Gr-1 + /CD11b + (a), Gr-1 + /CD11b " (b) and eGFP/Gr-1 + / CD11b + (c) cells. The data shown are the mean±SD of three combined experiments i.e. n59 mice per group. Asterisks indicate results that are significantly different (P,0.01; ANOVA, paired Student's t test). administered these to recipient, sex-matched, 6-8-weekold C57BL/6 mice (3610 7 cells in 200 ml PBS) via the tail vein (i.e. adoptive transfer). Twenty-four hours later, LPS with various concentrations of CBP-FLAG were injected into the dermis of the abdominal region of the recipients. A day later, mice were euthanized and cells were stained with CD11b and Gr-1 as described above. The results show that CBP-FLAG significantly inhibited the recruitment of blood-derived monocytes (eGFP Gr-1 + / CD11b + ) at 1 and 100 ng CBP-FLAG (Student's t test P,0.01) with the most potent inhibition seen at 100 ng CBP-FLAG (Fig. 2c ).
Finally, histology was performed to confirm the above findings. Mouse experiments were carried out as above; skin samples were treated with zinc salt fixative (González et al., 2001) and embedded in paraffin wax for cellular analysis. Multiple 5 mm sections were cut at 40 mm intervals. Adjacent sections were stained with haematoxylin and eosin (H & E) , CD11b marker [biotin-labelled CD11b, used at 1/200 dilution, with streptavidin-conjugated Alexa488 (1/50 dilution); R&D systems] and 3,39-diaminobenzidine (Sigma) for peroxidase granules (neutrophils). The H & E-stained sections show an accumulation of leukocytes in the thickened dermis of LPSinjected skin (Fig. 3a) . In contrast, skin co-injected with CBP-FLAG or CBP-FLAG+LPS showed no dermal thickening and fewer leukocytes. The LPS-injected skin also showed an increased accumulation of CD11b + cells but this was not seen when CBP was co-injected ( Fig. 3a, c) . The numbers of neutrophils were consistent between the LPS only and CBP-FLAG+LPS sections ( Fig. 3a and d) .
The ability of CBP-FLAG to inhibit the recruitment of monocytes in response to LPS-induced inflammation was similar for the adoptive transfer and non-adoptive transfer models. We also noticed that there were Gr-1 + (CD11b 2 ) cells recruited to the skin in response to LPS in both models. The Gr-1 + cells may represent neutrophils that largely respond to CXC chemokines. C57Bl/6 mice produce a Th1 dominant inflammatory response to LPS (Reiner & Locksley, 1993; Takeda et al., 2003) typical of a viral infection. Nevertheless, the dynamics of the cutaneous response induced with LPS will differ from that resulting from viral infection. The rapid transient upregulation of high levels of proinflammatory cytokines induced with LPS contrasts with the gradual cytokine response that characterizes viral infection. Despite the magnitude of the LPS response, nanogram quantities of CBP injected into the skin were able to effectively impair cellular trafficking.
The therapeutic potential of several poxvirus CBPs has been investigated in various rodent animal models. Cowpoxvirus vCCI was shown to suppress allergeninduced chronic pulmonary inflammation in BALB/cJ mice (Dabbagh et al., 2000) , whilst myxomavirus MT1 suppressed the inflammatory response that develops immediately after allograft transplant vasculopathy surgery (Liu et al., 2004) . The vaccinia virus 35 kDa protein has been shown to regulate leukocyte trafficking to the lungs during vaccinia virus infection (Reading et al., 2003) . The murine models we have employed demonstrate unequivocally that CBP-FLAG is a potent inhibitor of leukocyte recruitment in acute inflammatory skin responses. The potency of this molecule is within the physiological range within which such cellular immune molecules operate (10-60 ng ml 21 ; Conti et al., 1997; Fahey et al., 2005) . Furthermore, we have determined that approximately 60-120 ng CBP ml 21 is produced from recombinant ORFV infected cells in culture over a 2-5 day period (unpublished data). Our studies are the first to report the effects of a viral-encoded CBP on inflammatory cell trafficking to the skin and may have relevance to the treatment of inflammatory skin disorders. Fig. 3 . Histological analyses of the effects of CBP on inflammatory cell recruitment. C57BL/6 mice were injected in the abdominal skin with 1 mg LPS with or without 100 ng CBP (n52 animals per group). Twenty-four hours later, mice were euthanized and skin sections were excised and stained for various inflammatory cell types (a); these were H & E staining (leukocytes), CD11b + (monocytes) and peroxidase (neutrophils). (b-d) Cells [leukocytes (b), CD11b + monocytes (c) and neutrophils (d)] were quantified by counting in 10 high-powered fields (¾40 magnification). The data shown are the mean±SD.
